Forest Laboratories

Last updated
Forest Laboratories, Inc.
Industry Pharmaceutical industry
Founded1956 (1956)
DefunctJuly 1, 2014;9 years ago (July 1, 2014)
Headquarters New York City
Key people
Brenton L. Saunders (CEO)
RevenueIncrease2.svg $3.646 billion (2013)
Increase2.svg $165 million (2013)
Total assets Increase2.svg $12.017 billion (2013)
Total equity Increase2.svg $6.165 billion (2013)
Number of employees
6,200 (2013)
Footnotes /references
[1]

Forest Laboratories was a company in the pharmaceutical industry incorporated in Delaware, with its principal office in New York City. It was known for licensing European pharmaceuticals for sale in the United States. On July 1, 2014, the company was acquired by Actavis (now Allergan).

Contents

History

The company was founded by Hans Lowey in 1956 as a small laboratory service company. [2]

In 1967, the company became a public company via an initial public offering. [3]

Ten years later, Howard Solomon became the chief executive officer of the company. [3]

In 1984, the company acquired O'Neal Jones & Feldman for $8.8 million after a federal investigation resulted in one of its drugs being recalled. [4] [2]

On July 17, 1998, the company received approval from the Food and Drug Administration for Celexa (Citalopram), an antidepressant. [5]

In 2000, the company cut ties with Warner-Lambert for the marketing of Celexa after Warner-Lambert was acquired by Pfizer. [6]

On August 16, 2002, the company received approval from the Food and Drug Administration for Lexapro (Escitalopram), an updated version of Celexa. [7]

In 2013, Solomon retired as chief executive officer of the company. [8]

In February 2014, the company acquired Aptalis for $2.9 billion. [9]

On July 1, 2014, the company was acquired by Actavis (now Allergan). [10] The sale of the company came after pressure from Carl Icahn, the largest shareholder.

Products

Some of the products Forest Laboratories marketed with its partners included:

Controversies

Illegal distribution and promotion of medicines

In September 2010, the company agreed to pay $313 million to resolve allegations of civil and criminal liability relating to felony, obstruction of justice, and the illegal distribution and promotion of pharmaceuticals, charges to which it pled guilty. One of the pharmaceutical-related charges was a misdemeanor charge of illegally promoting the Celexa and Lexapro for unapproved uses in treating pediatric depression. The other drug-related charge was a misdemeanor charge of distributing the unapproved drug Levothroid in violation of the Federal Food, Drug, and Cosmetic Act. Certain of the criminal activities were revealed with the help of whistleblowers, who received $14 million from the settlement. [11] [12] [13]

Forest Laboratories has been accused of using unlawful deals to prevent generic versions of its Alzheimer's disease drug Namenda from entering the market. [14] [15]

Tax avoidance via transfer pricing

In 2010, the company was criticized for legally moving its profits offshore via transfer pricing. [16]

Notes

  1. "Forest Laboratories, Inc. 2013 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
  2. 1 2 DOYLE, JIM (October 4, 2010). "Forest's push for profits led to drugmaker's woes". St. Louis Post-Dispatch .
  3. 1 2 "A CEO and His Son". Bloomberg Businessweek . May 27, 2002.
  4. "BRIEFS". The New York Times . November 14, 1984.
  5. "Forest Labs' longtime CEO Solomon to step down at year-end". Food and Drug Administration. July 17, 1998.
  6. "Forest Labs cuts W-L tie". CNN . May 12, 2000.
  7. "FOREST AND LUNDBECK WIN APPROVAL FOR ANTIDEPRESSANT". The New York Times . Bloomberg News. August 16, 2002.
  8. Humer, Caroline (May 23, 2013). "Forest Labs' longtime CEO Solomon to step down at year-end". Reuters .
  9. "Forest Laboratories, Inc. Completes $2.9B Acquisition of Aptalis" (Press release). Business Wire. February 3, 2014.
  10. "Actavis Completes Forest Laboratories Acquisition" (Press release). PR Newswire. July 1, 2014.
  11. "OIG Fact Sheet on Forest Laboratories, Inc., and the Inspector General's Exclusion Authorities" (Press release). Office of Inspector General. May 10, 2011.
  12. Volkmann, Kelsey (September 15, 2010). "Forest Pharmaceuticals to plead guilty, pay $313M". American City Business Journals .
  13. Singer, Natasha (September 15, 2010). "Forest, Maker of Celexa, Settles Marketing Claims". The New York Times .
  14. "AbbVie subsidiary Forest faces more antitrust litigation over Alzheimer's drug as judge rejects its bid to toss case". FiercePharma. Retrieved 2022-02-06.
  15. Pierson, Brendan (2021-06-11). "AbbVie must face health plans' lawsuit over Alzheimer's drug". Reuters. Retrieved 2022-02-06.
  16. Drucker, Jesse (May 13, 2010). "Forest Laboratories' Globe-Trotting Profits". Bloomberg Businessweek .

Related Research Articles

<span class="mw-page-title-main">Hypothyroidism</span> Endocrine disease

Hypothyroidism is a disorder of the endocrine system in which the thyroid gland does not produce enough thyroid hormones. It can cause a number of symptoms, such as poor ability to tolerate cold, a feeling of tiredness, constipation, slow heart rate, depression, and weight gain. Occasionally there may be swelling of the front part of the neck due to goitre. Untreated cases of hypothyroidism during pregnancy can lead to delays in growth and intellectual development in the baby or congenital iodine deficiency syndrome.

<span class="mw-page-title-main">Escitalopram</span> SSRI antidepressant

Escitalopram, sold under the brand names Lexapro and Cipralex, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Escitalopram is mainly used to treat major depressive disorder and generalized anxiety disorder. It is taken by mouth, available commercially as an oxalate salt exclusively.

<span class="mw-page-title-main">Citalopram</span> SSRI antidepressant

Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, and social phobia. The antidepressant effects may take one to four weeks to occur. It is typically taken orally. In some European countries, it is sometimes given intravenously to initiate treatment, before switching to the oral route of administration for continuation of treatment. It has also been used intravenously in other parts of the world in some other circumstances.

Thyroid-stimulating hormone (also known as thyrotropin, thyrotropic hormone, or abbreviated TSH) is a pituitary hormone that stimulates the thyroid gland to produce thyroxine (T4), and then triiodothyronine (T3) which stimulates the metabolism of almost every tissue in the body. It is a glycoprotein hormone produced by thyrotrope cells in the anterior pituitary gland, which regulates the endocrine function of the thyroid.

<span class="mw-page-title-main">Lundbeck</span> International Pharmaceutical Firm

H. Lundbeck A/S is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine.

Aptalis was a company in the pharmaceutical industry. In January 2014, the company was acquired by Forest Laboratories for $675 million. Through a series of acquisitions, the company is now a contract development and manufacturing organization and rebranded as Adare Phama Solutions, headquartered in Lawrenceville, New Jersey.

<span class="mw-page-title-main">Warner Chilcott</span> American pharmaceutical company

Warner Chilcott was a company in the pharmaceutical industry based in Rockaway, New Jersey. It was primarily focused on women's healthcare and dermatology. On October 1, 2013, the company was acquired by Actavis.

<span class="mw-page-title-main">Memantine</span> Medication used to treat Alzheimers disease

Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is taken by mouth.

<span class="mw-page-title-main">Thyroid disease</span> Medical condition

Thyroid disease is a medical condition that affects the function of the thyroid gland. The thyroid gland is located at the front of the neck and produces thyroid hormones that travel through the blood to help regulate many other organs, meaning that it is an endocrine organ. These hormones normally act in the body to regulate energy use, infant development, and childhood development.

Thyroid function tests (TFTs) is a collective term for blood tests used to check the function of the thyroid. TFTs may be requested if a patient is thought to suffer from hyperthyroidism or hypothyroidism, or to monitor the effectiveness of either thyroid-suppression or hormone replacement therapy. It is also requested routinely in conditions linked to thyroid disease, such as atrial fibrillation and anxiety disorder.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

The number of new psychiatric drugs, and especially antidepressants on the market in Japan, is significantly less than Western countries.

<span class="mw-page-title-main">Linaclotide</span> Medicine

Linaclotide, is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause. It has a black box warning about the risk of serious dehydration in children in the US; the most common adverse effects in others include diarrhea.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Intractable pain, also called intractable pain syndrome (IPS), is a severe, constant, relentless, and debilitating pain that is not curable by any known means and which causes a house-bound or bed-bound state and early death if not adequately treated, usually with opioids and/or interventional procedures. It is not relieved by ordinary medical, surgical, nursing, or pharmaceutical measures. Unlike the more common chronic pain, it causes adverse biologic effects on the body's cardiovascular, hormone, and neurologic systems. Patients experience changes in testosterone, estrogen, cortisol, thyroid hormones, and/or pituitary hormones. Both men and women require testosterone, however many doctors neglect to test women for low testosterone. Untreated intractable pain can cause death.

The term "me-too drug" or "follow-on drug" refers to a medication that is similar to a pre-existing drug, usually by making minor modifications to the prototype, reflected in slight changes in the profiles of side effects or activity, and used to treat conditions for which drugs already exist. While pharmaceutical companies have justified the development of me-toos as offering incremental improvements in efficacy, side-effects, compliance and cost, critics have questioned the increasing marketing of me-toos, their absorption of research and development resources and their impact on the innovation of new treatments.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.